Predicting COPD Exacerbations 5 Days Early with 86% Accuracy

Life Detection Technologies (LDT) is a Boston-based innovator in improving patient monitoring.
LDT had the hardware and years of physiological data, but they faced a massive hurdle: determining if this raw data could actually predict chronic obstructive pulmonary disease (COPD) exacerbations before they happened.
They needed a secure, HIPAA compliant partner capable of deep research and development to turn raw signals into a life-saving medical device.

CHALLENGE

LDT faced three main challenges

Raw, Unstructured Sensor Data

LDT’s sensors collected massive amounts of "time-series" data, but it was just a raw sine waveform. To the naked eye, it was just noise. They needed a way to extract meaningful biomarkers—like heart rate, respiratory rate, and coughing—from a simple vibration signal.

Data without insight

Limited
Training Set

Unlike consumer apps with millions of users, LDT was working with a clinical study of only 20 to 30 patients. Building a machine learning model with such a small dataset creates a huge risk of "overfitting" (where the model cheats to get right answers). They needed a model that was accurate in the real world, not just in the lab.

High risk of inaccuracy

The FDA Approval Barrier

This wasn't just software; it was a medical device. Every technical decision required rigorous documentation, security audits, and HIPAA compliance to meet FDA standards. A standard dev shop wouldn't know how to build a pipeline ready for federal scrutiny.

Regulatory complexity

SOLUTION

How We Solved It

Working as an embedded R&D partner, we didn't just build to a spec—we investigated the unknown. We combined deep machine learning research with rigorous engineering to turn a "possibility" into a proven medical breakthrough.

Advanced Feature Engineering

We couldn't change the data, so we changed how the machine read it. We used Feature Engineering to break the raw sine waves down into hundreds of specific attributes.

Signal Conversion: We took the single raw waveform signal and expanded it into hundreds of distinct data attributes.

Anomaly Detection: We identified subtle "invisible" markers, such as changes in heart rate variability or specific cough patterns, that signal a patient is getting worse.

Predictive Machine Learning Models

We developed a sophisticated ML model (using CatBoost) that analyzes these features to predict exacerbations. By rigorously testing against "data leaks" and separating training sets, we achieved a stable algorithm that identifies 86% of exacerbations 5 days in advance.

Sensitivity: 86% (Identifying true positive cases)
Specificity: 95% (Avoiding false alarms)

FDA-Ready Infrastructure

We built the entire software ecosystem to be FDA-ready from day one. This included a HIPAA-compliant cloud architecture with over 380 security checks, automated compliance monitoring, and full audit trails required for their FDA submission.

IMPACT

What Did LDT Gain From Partnering With Us?

5 days

5-Day Advanced Warning

The algorithm predicts COPD exacerbations five days before hospitalization is required, offering a critical window for early intervention.

86% / 95%

86% Sensitivity / 95% Specificity

Achieved highly accurate clinical predictions using advanced feature engineering on limited patient datasets.

380+

380+ Security Controls

Implemented a HIPAA-compliant data pipeline with rigorous audit trails, fully prepared for FDA submission.

ERS

Global Medical Validation

Research results were accepted and presented at the prestigious European Respiratory Society (ERS) Congress in Amsterdam.

$$$

Secured Investor Confidence

Demonstrated consistent progress from raw sine waves to a working AI model, securing executive alignment and continued funding.

Predicting COPD Exacerbations 5 Days Early with 86% Accuracy

LDT faced three main challenges

Raw, Unstructured Sensor Data

Limited
Training Set

The FDA Approval Barrier

How We Solved It

Advanced Feature Engineering

Predictive Machine Learning Models

FDA-Ready Infrastructure

What Did LDT Gain From Partnering With Us?

5-Day Advanced Warning

86% Sensitivity / 95% Specificity

380+ Security Controls

Global Medical Validation

Secured Investor Confidence

Ready to take your medical innovation to FDA approval?

And That's How NineTwoThree Creates Compliant AI Solutions That Save Lives

Similar Case Studies

Used ML to Predict Thousands of Sales

Supporting Mobile Development for Over 100,000 users

Ready To Launch Your Project?

Predicting COPD Exacerbations 5 Days Early with 86% Accuracy

LDT faced three main challenges

Raw, Unstructured Sensor Data

Limited Training Set

The FDA Approval Barrier

How We Solved It

Advanced Feature Engineering

Predictive Machine Learning Models

FDA-Ready Infrastructure

What Did LDT Gain From Partnering With Us?

5-Day Advanced Warning

86% Sensitivity / 95% Specificity

380+ Security Controls

Global Medical Validation

Secured Investor Confidence

Ready to take your medical innovation to FDA approval?

And That's How NineTwoThree Creates Compliant AI Solutions That Save Lives

Similar Case Studies

Used ML to Predict Thousands of Sales

Supporting Mobile Development for Over 100,000 users

Ready To Launch Your Project?

Limited
Training Set